Drug facts
MoleculeMemantine
Generics already compete: 23 makers on the market. 68 A-rated products from 23 makers substitute at the counter.
Namenda was first approved by the FDA on 10/16/2003 under NDA 021487; the application holder is Abbvie Inc. The Orange Book lists NDA 021487 as discontinued.
The latest NADAC for MEMANTINE HCL ER 28 MG CAPSULE is $0.33 per unit (as of 10/28/2026).
Holder Abbvie IncApplication NDA 021487Approved 10/16/2003
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Namenda patent listed in the Orange Book Orange Book
- Later patents, other products
- Namenda XR 09/24/2029 Orange Book
02Competition
- Generics
- 23 generic makers Orange Book
- First generic approved
- 04/14/2010 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Memantine profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.33 per unitMEMANTINE HCL ER 28 MG CAPSULE, mid-priced of 4 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 03/24/2026Class II, Memantine Hydrochloride Extended-Release, The Harvard Drug Group LLC FDA enforcement
04Product
- Application holder
- Abbvie Inc Orange Book
- Application
- NDA 021487 Orange Book
- First approved
- 10/16/2003 Orange Book
- Dosage forms
- capsule, extended release; solution; tablet
- Routes
- oral
- Status
- NDA 021487 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.